Stivala, Simona

Codilupi, Tamara; Szybinski, Jakub; Arunasalam, Stefanie; Jungius, Sarah; Dunbar, Andrew C; Stivala, Simona; Brkic, Sime; Albrecht, Camille; Vokalova, Lenka; Yang, Julie L; Buczak, Katarzyna; Ghosh, Nilabh; Passweg, Jakob R; Rovo, Alicia; Angelillo-Scherrer, Anne; Pankov, Dmitry; Dirnhofer, Stephan; Levine, Ross L; Koche, Richard and Meyer, Sara C (2024). Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable. Clinical cancer research, 30(3), pp. 586-599. American Association for Cancer Research 10.1158/1078-0432.CCR-23-0163

Stivala, Simona; Meyer, Sara C. (2021). Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms. Cancers, 13(20) MDPI AG 10.3390/cancers13205035

Brkic, Sime; Stivala, Simona; Santopolo, Alice; Szybinski, Jakub; Jungius, Sarah; Passweg, Jakob R; Tsakiris, Dimitrios; Dirnhofer, Stefan; Hutter, Gregor; Leonards, Katharina; Lischer, Heidi E L; Dettmer, Matthias S; Neel, Benjamin G; Levine, Ross L; Meyer, Sara C (2021). Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia, 35(10), pp. 2875-2884. Springer Nature 10.1038/s41375-021-01391-2

Mathis, Alexandra; Villiger, Lukas; Reiner, Martin F; Egloff, Michael; Schmid, Hans Ruedi; Stivala, Simona; Limacher, Andreas; Méan, Marie; Aujesky, Drahomir; Rodondi, Nicolas; Angelillo, Anne; Righini, Marc; Staub, Daniel; Aschwanden, Markus; Frauchiger, Beat; Osterwalder, Joseph; Kucher, Nils; Matter, Christian M; Banyai, Martin; Hugli, Oliver; ... (2020). Elevated HbA1c is not associated with recurrent venous thromboembolism in the elderly, but with all-cause mortality- the SWEETCO 65+ study. Scientific Reports, 10(1), p. 2495. Nature Publishing Group 10.1038/s41598-020-59173-2

Stivala, Simona; Codilupi, Tamara; Brkic, Sime; Baerenwaldt, Anne; Ghosh, Nilabh; Hao-Shen, Hui; Dirnhofer, Stephan; Dettmer, Matthias S.; Simillion, Cedric; Kaufmann, Beat A; Chiu, Sophia; Keller, Matthew; Kleppe, Maria; Hilpert, Morgane; Buser, Andreas S; Passweg, Jakob R; Radimerski, Thomas; Skoda, Radek C; Levine, Ross L and Meyer, Sara C (2019). Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. The journal of clinical investigation, 129(4), pp. 1596-1611. American Society for Clinical Investigation 10.1172/JCI98785

Stivala, Simona; Gobbato, Sara; Infanti, Laura; Reiner, Martin F; Bonetti, Nicole; Meyer, Sara C.; Camici, Giovanni G; Lüscher, Thomas F; Buser, Andreas; Beer, Juerg H (2017). In response to the comment by Hechler et al.: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica - the hematology journal, 102(12), e504-e505. Ferrata-Storti Foundation 10.3324/haematol.2017.181818

Stivala, Simona; Gobbato, Sara; Infanti, Laura; Reiner, Martin F; Bonetti, Nicole; Meyer, Sara C.; Camici, Giovanni G; Lüscher, Thomas F; Buser, Andreas; Beer, Jürg H (2017). Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica - the hematology journal, 102(10), pp. 1650-1660. Ferrata-Storti Foundation 10.3324/haematol.2017.164137

Reiner, Martin F; Stivala, Simona; Limacher, Andreas; Bonetti, Nicole R; Méan, Marie; Egloff, Michael; Rodondi, Nicolas; Aujesky, Drahomir; von Schacky, Clemens; Lüscher, Thomas F; Camici, Giovanni G; Beer, Jürg H (2017). Omega-3 Fatty Acids Predict Recurrent Venous Thromboembolism or Total Mortality in Elderly Patients with Acute Venous Thromboembolism. Journal of thrombosis and haemostasis, 15(1), pp. 47-56. Wiley-Blackwell 10.1111/jth.13553

Meyer, Sara C; Ghosh, Nilabh; Stivala, Simona; Baerenwaldt, Anne; Hao-Shen, Hui; Dirnhofer, Stefan; Dettmer, Matthias; Simillion, Cédric; Chiu, Sophia; Keller, Matthew; Kleppe, Maria; Hilpert, Morgane; Buser, Andreas S.; Passweg, Jakob R.; Radimersk, Thomas; Skoda, Radek C.; Levine, Ross L. (2017). Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms. Blood, 130(Suppl. 1), p. 381. American Society of Hematology